| Suspended | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma NCT06806228 | Petrov, Andrey | Phase 1 |
| Not Yet Recruiting | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) NCT07389278 | Sabine Mueller, MD, PhD | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors NCT06357377 | Neonc Technologies, Inc. | Phase 1 |
| Recruiting | Atovaquone Combined With Radiation in Children With Malignant Brain Tumors NCT06624371 | Emory University | Phase 1 |
| Recruiting | Study of Olutasidenib and Temozolomide in HGG NCT06161974 | Rigel Pharmaceuticals | Phase 2 |
| Recruiting | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | Targeted Pediatric High-Grade Glioma Therapy NCT05839379 | Nationwide Children's Hospital | — |
| Recruiting | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in NCT06305910 | OX2 Therapeutics | Phase 1 |
| Not Yet Recruiting | RE-irradiation of Diffuse MIdline Glioma paTients NCT06093165 | Rigshospitalet, Denmark | N/A |
| Recruiting | CAR T Cells to Target GD2 for DMG NCT05544526 | University College, London | Phase 1 |
| Active Not Recruiting | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Muta NCT05478837 | University of California, San Francisco | Phase 1 |
| Recruiting | FUS Etoposide for DMG NCT05762419 | Columbia University | Phase 1 |
| Recruiting | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors NCT05835687 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-N NCT05259605 | European Organisation for Research and Treatment of Cancer - EORTC | — |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 NCT05476939 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Recruiting | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG NCT04943848 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 |
| Recruiting | Combination Therapy for the Treatment of Diffuse Midline Gliomas NCT05009992 | University of California, San Francisco | Phase 2 |
| Recruiting | Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study NCT05077735 | Mayo Clinic | Phase 2 |
| Terminated | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glio NCT04804709 | Columbia University | Phase 1 |
| Terminated | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline NCT04771897 | Bexion Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms NCT04541082 | Jazz Pharmaceuticals | Phase 1 |
| Completed | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas NCT02960230 | Sabine Mueller, MD, PhD | Phase 1 / Phase 2 |
| Completed | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gl NCT01922076 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository NCT03101813 | Children's Hospital Medical Center, Cincinnati | — |
| No Longer Available | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered NCT05518838 | Oblato, Inc. | — |